Faculty profile

Enrique Sanz Garcia

ResearcherRadiation OncologyUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

Enrique Sanz Garcia

Researcher

Radiation Oncology

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
28 publications in the last five years, latest in 2026.
Senior (last) author on 2 recent papers, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2025.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Adaptive Therapy Ctdna De-Escalation Head And Neck Cancer Hpv Personalized Medicine Radiotherapy Surgery

Latest papers

HPV Serology and Circulating Viral DNA for Detection, Genotyping, and Measurement of Disease Burden in Oropharyngeal Cancer.
International journal of cancer · 2026
Validation of the ninth edition pathological and clinical TNM classifications for salivary gland carcinoma.
Oral oncology · 2026
Metastatic patterns, outcomes, and prognostic factors in de novo metastatic head and neck cancer by tumor HPV status.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026

All 29 publications

Latest funding

The TITRATE (Tailored Intensity of Treatment with Radio(chemo)therapy After Timely Evaluation) study: Toward personalized de-escalated multimodal therapy for oropharynx cancer
CIHR · 2025 · Principal investigator
$1,071,000

All 1 grants and awards

29 publications.

HPV Serology and Circulating Viral DNA for Detection, Genotyping, and Measurement of Disease Burden in Oropharyngeal Cancer.

Penny L, Stutheit-Zhao EY, Michels BE, Rosing F, Zhao Z, Zheng Y, Zou J, Huang SH, Carlton J, McPartlin A, de Almeida JR, Goldstein D, Hope A, Hosni A, Kim J, Liu FF, Tsai CJ, Waldron JN, Spreafico A, Sanz-Garcia E, Siu LL, Waterboer T, Liu G, Bratman SV

International journal of cancer2026

DOI: 10.1002/ijc.70619 PMID: 42380047

Validation of the ninth edition pathological and clinical TNM classifications for salivary gland carcinoma.

Alsulami S, Rühle A, Yu E, Su J, O'Sullivan B, Hosni A, Waldron JN, Weinreb I, Smith S, de Almeida J, Goldstein D, Yao CM, McPartlin A, Bayley A, Bratman SV, Hahn E, Hope A, Kim J, Malik N, Sanz-Garcia E, Spreafico A, Tong L, Xu W, Bartlett E, Huang SH

Oral oncology2026

DOI: 10.1016/j.oraloncology.2026.108140 PMID: 42732755

Metastatic patterns, outcomes, and prognostic factors in de novo metastatic head and neck cancer by tumor HPV status.

Rühle A, Sanz-Garcia E, Su J, O'Sullivan B, Waldron JN, Spreafico A, Siu L, Eng L, McPartlin A, Bayley A, Bratman SV, Hahn E, Hope A, Hosni A, Malik N, Tsai J, de Almeida J, Xu W, Kim J, Huang SH

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2026

DOI: 10.1016/j.radonc.2026.111769 PMID: 42697275

EphA4 Mediates Pro- and Antitumoral Effects Through Upstream Negative Regulation of AKT in Head and Neck Squamous Cell Carcinoma.

Corbo S, Abdelazeem KNM, Nguyen D, Bhatia S, Van Court B, Olimpo NA, Gadwa J, Hodgson CA, Beynor JI, Samedi VG, Sanz-Garcia E, Siu LL, Saviola AJ, Heasley LE, Pasquale EB, Knitz MW, Karam SD

Cancer immunology research2026

DOI: 10.1158/2326-6066.cir-25-1353 PMID: 42644611

Disease Site-Specific Outcomes in p16-Positive Non-Oropharyngeal Mucosal Head and Neck Cancer.

Chelvarajah RC, Chee LYS, Su J, O'Sullivan B, Yao CMKL, Sanz-Garcia E, Smith SM, Weinreb I, Bratman S, Cho BCJ, Hahn E, Hope A, Hosni A, Kim J, McPartlin A, Malik N, Tsai CJ, de Almeida J, Spreafico A, Tong L, Huang SH, Waldron JN

Head & neck2026

DOI: 10.1002/hed.70230 PMID: 41816946

Impact of metastasis-directed therapy for metachronous thoracic metastases following definitive (chemo)radiotherapy in p16-positive head and neck squamous cell carcinoma.

Ly S, Rühle A, Bratman S, Cho J, Hosni A, Hahn E, Kim J, McPartlin A, Ringash J, O'Sullivan B, Tsai CJ, Waldron J, Goldstein D, Sanz-Garcia E, Spreafico A, Su J, Tong L, Weinreb I, Huang SH, Hope A

Oral oncology2026

DOI: 10.1016/j.oraloncology.2026.108006 PMID: 42127862

Prevalence and Prognostic Value of Individual T4-Defining Radiologic Features in Human Papillomavirus-Positive Oropharyngeal Carcinoma.

Johari MH, Rühle A, Su J, O'Sullivan B, Yu E, Waldron JN, McPartlin A, Bayley A, Bratman SV, Sanz-Garcia E, Spreafico A, de Almeida J, Hahn E, Hope A, Hosni A, Kim J, Malik N, Xu W, Bartlett E, Huang SH

International journal of radiation oncology, biology, physics2026

DOI: 10.1016/j.ijrobp.2025.12.032 PMID: 41448500

Pan-Cancer Pre-Treatment ctDNA Detection Using a Highly Sensitive Tumor-Informed Assay.

Strum S, Murray C, Genta S, Sanz-Garcia E, Razak A, Lheureux S, Pipinikas C, Wang BX, Chevalier A, Smith CG, Spreafico A, Siu LL, Elliott M, Cescon DW

International journal of molecular sciences2026

DOI: 10.3390/ijms27093979 PMID: 42123559

Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial.

Capdevila J, Hernando J, Molina-Cerillo J, Plana Serrahima M, Taberna Sanz M, Castelo B, Álvarez-Escolá C, Carmona-Bayonas A, Ballester Navarro I, Iglesias L, Bover M, Garcia-Alvarez A, Lavernia J, Yayá Tur R, Ruiz S, Baste N, Lorenzo-Lorenzo I, Sanchez-Hernandez A, Sanz-Garcia E, Marquina G, Nuciforo P, Elguero B, Grande E, Alonso-Gordoa T

Nature communications2026

DOI: 10.1038/s41467-026-71155-y PMID: 41935063

Investigating Early Kinetics in Plasma ctDNA and Peripheral T-cell Receptor Repertoire to Predict Treatment Outcomes to PD-1 Inhibitors in Head and Neck Squamous Cell Carcinoma.

Sanz-Garcia E, Soleimani S, Bruce JP, Pedersen S, Tang M, Avery L, Eagles J, Spreafico A, Hansen AR, Eng L, Laliotis G, Krainock M, Liu M, Basra P, Yu C, Felicen S, Ohashi PS, Bratman SV, Pugh TJ, Siu LL

Clinical cancer research : an official journal of the American Association for Cancer Research2026First author

DOI: 10.1158/1078-0432.ccr-25-3541 PMID: 41417470

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2025

Subject: Prospective PhD student: Adaptive Therapy Dear Professor Sanz Garcia, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "HPV Serology and Circulating Viral DNA for Detection, Genotyping, and Measurement of Disease Burden in Oropharyngeal Cancer." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "The TITRATE (Tailored Intensity of Treatment with Radio(chemo)therapy After Timely Evaluation) study: Toward personalized de-escalated multimodal therapy for oropharynx cancer" (2025), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Enrique Sanz Garcia

Research

Latest papers

Latest funding

HPV Serology and Circulating Viral DNA for Detection, Genotyping, and Measurement of Disease Burden in Oropharyngeal Cancer.

Validation of the ninth edition pathological and clinical TNM classifications for salivary gland carcinoma.

Metastatic patterns, outcomes, and prognostic factors in de novo metastatic head and neck cancer by tumor HPV status.

EphA4 Mediates Pro- and Antitumoral Effects Through Upstream Negative Regulation of AKT in Head and Neck Squamous Cell Carcinoma.

Disease Site-Specific Outcomes in p16-Positive Non-Oropharyngeal Mucosal Head and Neck Cancer.

Impact of metastasis-directed therapy for metachronous thoracic metastases following definitive (chemo)radiotherapy in p16-positive head and neck squamous cell carcinoma.

Prevalence and Prognostic Value of Individual T4-Defining Radiologic Features in Human Papillomavirus-Positive Oropharyngeal Carcinoma.

Pan-Cancer Pre-Treatment ctDNA Detection Using a Highly Sensitive Tumor-Informed Assay.

Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial.

Investigating Early Kinetics in Plasma ctDNA and Peripheral T-cell Receptor Repertoire to Predict Treatment Outcomes to PD-1 Inhibitors in Head and Neck Squamous Cell Carcinoma.

The TITRATE (Tailored Intensity of Treatment with Radio(chemo)therapy After Timely Evaluation) study: Toward personalized de-escalated multimodal therapy for oropharynx cancer

Frequent collaborators

Anna Spreafico

Andrew Hope

Wei Xu

John Kim

John de Almeida

Stephanie Lheureux

Lisa Avery

Scott Bratman

Lawson Eng

Benjamin Haibe-Kains

Geoffrey Liu

Eitan Prisman

Lillian Siu

Anand Govindarajan

Mathieu Lupien

Robert Olson

Fei-Fei Liu

Anand Ghanekar

Gelareh Zadeh

Faiyaz Notta

Philip Awadalla

Enrique Sanz Garcia

Research

Latest papers

Latest funding

HPV Serology and Circulating Viral DNA for Detection, Genotyping, and Measurement of Disease Burden in&#xa0;Oropharyngeal Cancer.

Validation of the ninth edition pathological and clinical TNM classifications for salivary gland carcinoma.

Metastatic patterns, outcomes, and prognostic factors in de novo metastatic head and neck cancer by tumor HPV status.

EphA4 Mediates Pro- and Antitumoral Effects Through Upstream Negative Regulation of AKT in Head and Neck Squamous Cell Carcinoma.

Disease Site-Specific Outcomes in p16-Positive Non-Oropharyngeal Mucosal Head and Neck Cancer.

Impact of metastasis-directed therapy for metachronous thoracic metastases following definitive (chemo)radiotherapy in p16-positive head and neck squamous cell carcinoma.

Prevalence and Prognostic Value of Individual T4-Defining Radiologic Features in Human Papillomavirus-Positive Oropharyngeal Carcinoma.

Pan-Cancer Pre-Treatment ctDNA Detection Using a Highly Sensitive Tumor-Informed Assay.

Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial.

Investigating Early Kinetics in Plasma ctDNA and Peripheral T-cell Receptor Repertoire to Predict Treatment Outcomes to PD-1 Inhibitors in Head and Neck Squamous Cell Carcinoma.

The TITRATE (Tailored Intensity of Treatment with Radio(chemo)therapy After Timely Evaluation) study: Toward personalized de-escalated multimodal therapy for oropharynx cancer

Frequent collaborators

Anna Spreafico

Andrew Hope

Wei Xu

John Kim

John de Almeida

Stephanie Lheureux

Lisa Avery

Scott Bratman

Lawson Eng

Benjamin Haibe-Kains

Geoffrey Liu

Eitan Prisman

Lillian Siu

Anand Govindarajan

Mathieu Lupien

Robert Olson

Fei-Fei Liu

Anand Ghanekar

Gelareh Zadeh

Faiyaz Notta

Philip Awadalla

HPV Serology and Circulating Viral DNA for Detection, Genotyping, and Measurement of Disease Burden in Oropharyngeal Cancer.